PMID- 37627318
OWN - NLM
STAT- MEDLINE
DCOM- 20230828
LR  - 20230828
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 13
IP  - 8
DP  - 2023 Aug 16
TI  - Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects 
      Their Pathogenesis.
LID - 10.3390/biom13081253 [doi]
LID - 1253
AB  - Ovarian clear cell (OCCC) and endometrioid (EnOC) carcinomas are often subsumed 
      under the umbrella term "endometriosis-associated ovarian cancer" (EAOC), since 
      they frequently arise from ectopic endometrium settled in the ovaries. The 
      phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of 
      rapamycin (mTOR) pathway is known to be aberrantly activated both in 
      endometriosis and EAOC; however, its role in the progression of endometriosis to 
      ovarian cancer remains unclear. In fact, cancer-associated alterations in the 
      mTOR pathway may be found in normal uterine epithelium, likely acting as a first 
      step towards ovarian cancer, through the intermediary stage of endometriosis. 
      This review aims to summarize the current knowledge regarding mTOR signaling 
      dysregulation in the uterine endometrium, endometriosis, and EAOC while focusing 
      on the interconnections between the PI3K/AKT/mTOR pathway and other signaling 
      molecules that give rise to synergistic molecular mechanisms triggering ovarian 
      cancer development in the presence of endometriosis.
FAU - Driva, Tatiana S
AU  - Driva TS
AUID- ORCID: 0000-0002-9511-6393
AD  - First Department of Pathology, Medical School, National and Kapodistrian 
      University of Athens, 11527 Athens, Greece.
FAU - Schatz, Christoph
AU  - Schatz C
AUID- ORCID: 0000-0001-8017-3400
AD  - Institute of Pathology, Neuropathology and Molecular Pathology, Medical 
      University of Innsbruck, 6020 Innsbruck, Austria.
FAU - Haybaeck, Johannes
AU  - Haybaeck J
AD  - Institute of Pathology, Neuropathology and Molecular Pathology, Medical 
      University of Innsbruck, 6020 Innsbruck, Austria.
AD  - Diagnostic & Research Center for Molecular Biomedicine, Institute of Pathology, 
      Medical University of Graz, 8010 Graz, Austria.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230816
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
SB  - IM
MH  - Female
MH  - Humans
MH  - Proto-Oncogene Proteins c-akt
MH  - Phosphatidylinositol 3-Kinases
MH  - *Endometriosis
MH  - *Ovarian Neoplasms
MH  - TOR Serine-Threonine Kinases
MH  - Phosphatidylinositol 3-Kinase
MH  - *Carcinoma
PMC - PMC10452661
OTO - NOTNLM
OT  - ARID1A mutations
OT  - PI3K/AKT/mTOR pathway
OT  - endometriosis
OT  - endometrium
OT  - ovarian cancer
COIS- The authors declare no conflict of interest.
EDAT- 2023/08/26 10:44
MHDA- 2023/08/28 07:16
PMCR- 2023/08/16
CRDT- 2023/08/26 01:05
PHST- 2023/07/16 00:00 [received]
PHST- 2023/08/05 00:00 [revised]
PHST- 2023/08/14 00:00 [accepted]
PHST- 2023/08/28 07:16 [medline]
PHST- 2023/08/26 10:44 [pubmed]
PHST- 2023/08/26 01:05 [entrez]
PHST- 2023/08/16 00:00 [pmc-release]
AID - biom13081253 [pii]
AID - biomolecules-13-01253 [pii]
AID - 10.3390/biom13081253 [doi]
PST - epublish
SO  - Biomolecules. 2023 Aug 16;13(8):1253. doi: 10.3390/biom13081253.